Enfortumab vedotin-ejfv (solution)
Based on 1 publication(s) in Google Scholar
Enfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate (ADC). Enfortumab vedotin-ejfv (solution) is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv (solution) is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.78%
- CAS No.: 1346452-25-2
- 분자량:152000 (average)
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Enfortumab vedotin-ejfv (solution)
More
Biological Activity
Enfortumab vedotin-ejfv is a humanized, monoclonal ADC that binds to a protein expressed on the surface of cancer cells, Nectin-4. When Enfortumab vedotin-ejfv binds to Nectin-4 on cells, it is internalized into the cell which allows proteases to break down the linker and MMAE is released. MMAE impairs the microtubule network within the cell, blocking mitosis and subsequently leading to cell death[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1346452-25-2
-
Appearance Liquid
-
분자량 152000 (average)
-
Color Colorless to light yellow
-
SMILES
[Enfortumab vedotin-ejfv (solution)]
-
선적
Shipping with dry ice.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
순도&문서
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Halford Z, et al. Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma. Ann Pharmacother. 2021;55(6):772-782. [Content Brief]
[2]. Mantia CM, et al. Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma. Expert Rev Anticancer Ther. 2022;22(5):449-455. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Enfortumab vedotin-ejfv (solution) Related Classifications
HY-P99016B Related Classifications
Powered by Bioz
- Enfortumab vedotin-ejfv (solution)
- 1346452-25-2
- Antibody-Drug Conjugates (ADCs)
- Nectin-4
- treatment‐related toxicity
- antibody-drug conjugate
- Enfortumab Vedotin
- nectin-4
- adverse events
- antibody drug conjugate
- enfortumab vedotin
- metastatic urothelial cancer
- urothelial carcinoma
- antibody–drug conjugates
- Antibody-drug conjugate
- MMAE
- Inhibitor
- inhibitor
- inhibit